MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Начало・Списък с акции・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

47.86 3.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

45.97

Максимум

49.41

Ключови измерители
By Trading Economics
Приходи	-34M -248M
Марж на печалбата	-74.379
Служители	700
EBITDA	-24M -261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+52.9% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.8B 8.7B
Предишно отваряне	44.76
Предишно затваряне	47.86

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

40.67 / 41.96 Подкрепа & съпротива

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.10.2025 г., 20:45 ч. UTC

Печалби

Costco Wholesale Sales Climb in September, Early October

8.10.2025 г., 20:12 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

TaskUs Shares Fall After Holders Reject Take-Private Deal

8.10.2025 г., 16:39 ч. UTC

Значими двигатели на пазара

Mining Shares Rise as Gold Prices Soar

8.10.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

8.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Profit-Taking -- Market Talk

8.10.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Finance Acquisition Using Internal Funds

8.10.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8.10.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8.10.2025 г., 21:54 ч. UTC

Пазарно говорене

Печалби

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8.10.2025 г., 21:30 ч. UTC

Пазарно говорене

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8.10.2025 г., 21:26 ч. UTC

Пазарно говорене

Печалби

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 19:15 ч. UTC

Пазарно говорене

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8.10.2025 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8.10.2025 г., 18:47 ч. UTC

Пазарно говорене

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Will Remain a Publicly Traded Co >TASK

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8.10.2025 г., 18:07 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Edging Up in September -- Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.10.2025 г., 15:57 ч. UTC

Пазарно говорене

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8.10.2025 г., 15:56 ч. UTC

Пазарно говорене

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8.10.2025 г., 15:53 ч. UTC

Пазарно говорене

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8.10.2025 г., 15:43 ч. UTC

Придобивния, сливания и поглъщания

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8.10.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

52.9% нагоре

12-месечна прогноза

Среден 71.22 USD 52.9%

Висок 80 USD

Нисък 37.91 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на REVOLUTION Medicines Inc през последните 3 месеца.

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.